B+
Bull case
25%
Probability
Target price
$2.61
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
BTMD
bioteANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.30
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-18
Recent news sentiment (30D)
-0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+76.7
Score
AI commentary
News tone is negative-to-mixed, centered on the recall, Q2 earnings pressure, and lower full-year guidance. The company source confirms sequential second-half improvement expectations, but the market has limited evidence that the recovery is underway. Analyst revision data and direct peer valuation support are limited; social, options, short-interest, and employee data are unavailable.
RankAlpha Sentiment Codex - 2026-08-18
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-05eventQ2 earnings miss and outlook resetHigh impact
The SEC-reported Q2 results showed revenue of $44.2 million, a 9.5% year-over-year decline, procedure revenue down 13.9%, gross margin at 65.4%, and adjusted EBITDA margin at 12.6%. Stored Zacks earnings context reports break-even adjusted EPS versus $0.03 consensus and revenue 5.71% below consensus. Management revised 2026 guidance to revenue above $175 million and adjusted EBITDA above $25 million. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-06]
2026-11-16catalystRecall normalization and procedure recoveryHigh impact
Management expects sequential procedure-revenue improvement in Q3 and Q4 as Asteria Health inventory normalizes, but still expects negative year-over-year procedure growth in both periods. Margin recovery depends on reduced reliance on higher-cost replacement suppliers and improved manufacturing efficiency. [#SEC-8K-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-18 • Updated nightlySource: Internal modelMethodology